Showing 971-980 of 8892 results for "".
Crisis Management: Office Operations, Part 1
https://practicaldermatology.com/topics/practice-management/crisis-management-office-operations-part-1/18181/How are primarily cosmetic dermatology practices dealing with shutdowns and preparing for the future? Host Neal Bhatia, MD discusses with Deirdre Hooper, MD, Ashish Bhatia, MD, Kevin Pinski, MD, and Nancy Samolitis, MD.Antibiotics and Cosmetic Trends; Seysara Launches
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-antibiotics-and-cosmetics-trends-seysara-launches/19532/Dermatologists are prescribing fewer antibiotics to manage acne and rosacea. But, the use of antibiotics after surgical procedures is on the rise. More than one third of American adults are considering a cosmetic treatment in 2019, results of a RealSelf survey show. Seysara (sarecycline), a novel teSkin of Color Session: Dr. Harris
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/skin-of-color-session-dr-harris/32683/John E. Harris, MD, PhD, summarizes his vitiligo talk from the "Skin of Color Session" at Maui Derm 2025, during which he covered new therapeutic options for vitiligo as well as promising drugs in the pipeline and why they could be so impactful.Journal Club: Efficacy of Systemics After Discontinuation
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-efficacy-of-systemics-after-discontinuation/32829/Practical Dermatology chief medical editor Neal Bhatia, MD, FAAD, is joined by Naiem T. Issa, MD, PhD, to discuss an article Dr. Issa authored reviewing published literature on the efficacy of biologics as monotherapy for atopic dermatitis following discontinuation. Issa NT, Abdin R, et al.Expanded Indications for UltraClear Cold Ablative Fractional Fiber Laser
https://practicaldermatology.com/series/c-suite-chats/expanded-indications-ultraclear-cold-ablative-fractional-fiber-laser/26268/Shlomo Assa, President and Co-Founder of Acclaro Medical, discusses the versatility of the UltraClear Cold Ablative Fractional Fiber Laser, which recently received FDA clearance to treat benign pigmented lesions and vascular dyschromia.Clinical Conversations: Risks vs Benefits of JAK Inhibitors
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-risks-vs-benefits-of-jak-inhibitors/20108/Clinical data for JAK inhibitors show clear benefits for many patients. But these drugs are associated with certain risks and class warnings. Matt Zirwas, MD and Adelaide Hebert, MD describe how they weigh risks, educate patients, and optimize long-term management.DermWireTV: Arcutis Survey on PsO Impact; Tinted Sunscreen Update; Cosmetic Interventions and Illness; Dr. Seemal Desai Elected
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-arcutis-survey-on-pso-impact-tinted-sunscreen-update-cosmetic-interventions-and-illness-dr-seema-desai-elected/20089/Arcutis Biotherapeutics' survey finds Individuals with psoriasis who use topical treatments want more effective and simpler interventions. Intertriginous disease poses particular challenges. Increased availability of tinted sunscreens could increase the use of SPF among individuals with darker skinScientifically Speaking: Sunscreen Update from Terri Michele, MD of the FDA CDER
https://practicaldermatology.com/topics/skin-cancer-photoprotection/scientifically-speaking-sunscreen-update-from-terri-michele-md-of-the-fda-cder/19853/What is the latest on sunscreen labeling? What are implications of recent serology studies? And could new screening agents come to the US market? Host Joel L. Cohen, MD talks to Terri Michele, MD, Director of the Office of Nonprescription Drugs in FDA CDER about these and other hot topics in sun proInsights on Care for Skin of Color, Part 2
https://practicaldermatology.com/topics/skin-of-color/insights-on-care-for-skin-of-color-part-2/18185/Hilary Baldwin, MD and James Q. Del Rosso, DO continue their discussion with host Neal Bhatia, MD about managing skin of color. They address long-term management strategies and the need for cultural awareness.DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A four